- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02604121
Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity (Cytobuccale)
Interest of Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity by Transepithelial Brushing in Liquid-based
Prospective study of diagnosis validation of a cytological technique. 200 patients with oral cavity cancerous and precancerous lesions will be enrolled.
A cytological sample of the lesion will be performed by transepithelial brushing ( Orcellex® Rovers brush) in cytology liquid-based technology (methode ThinPrep 2000 (Hologic®)). A microscopic double blind reading will be performed. A biopsy sampling will be carried out in accordance with current strategy of screening. The brushing diagnosis quality will be compared to the biopsy which is the gold standard.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31059
- University Hospital toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- one or several cancerous or pre-cancerous lesions of oral cavity newly diagnosed or detected during a follow-up visit
Exclusion Criteria:
- pregnant or lactating women
- patients under juridical protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: transepithelial brushing
transepithelial brushing in liquid-based technology + biopsy
|
transepithelial brushing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic validity of lesion (Bethesda system, 2001)
Time Frame: baseline
|
Diagnostic validity (specificity and sensibility, the classification of lesions is performed according Bethesda system, 2001 and the reference is the histology of biopsy of lesion
|
baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic validity - predictive value (positive and negative)
Time Frame: baseline
|
Calculation of predictive value (positive and negative) of cytology / the reference is histology of biopsy
|
baseline
|
|
Feasibility of cytology
Time Frame: Baseline
|
sample rate not satisfactory= hemorrhage hiding the cells of interest
|
Baseline
|
|
Feasibility of cytology
Time Frame: Baseline
|
sample rate not satisfactory : low cellularity of the material
|
Baseline
|
|
Reproducibility intra and inter observers (coefficient of kappa de cohen)
Time Frame: Baseline
|
reproducibility intra and inter observers of cytology interpretation (kappa de cohen)
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Laetitia COLIN-LACOSTE, MD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12 045 03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.